SIRPA and ovarian carcinoma: Then we assessed the activity of CD47 blockade therapy with SIRPa-Fc decoy receptor (TTI-621) using intraperitoneal (IP) xenograft ovarian cancer models with three ovarian cancer cell lines (TOV-21G, OVCAR3 and SKOV3).